How to use a MASLD Pathway

Join Dr Davis from the RBWH as we discuss SIRT, radiation segmentectomy when treating HCC. Covering response rates, curative vs palliative therapy and steps to performing SIRTFor further reading check out: https://pubmed.ncbi.nlm.nih.gov/38495257/

Join Prof Tsochatzis as we discuss MASLD Pathway, covering who should be screened, sensitivity of ultrasound, intrpreting iron studies and the impact of alcohol. Also check out The Lancet review article - Screening for advanced steatotic liver disease - https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00097-4/abstract

Join Prof Emmanuel Tsochatzis as we discuss on interpreting and utilising NITs in assessing MASLD. Detecting at-risk steatotic liver disease and liver fibrosis in the community: https://journals.lww.com/hep/fulltext/9900/detecting_at_risk_steatotic_liver_disease_and.1285.aspx

Join Dr Rohit Gupta as we discuss second line treatment for PBC covering treatment, impact on symptoms, advanced cirrhosis and managing patients on fenofibrate. With Elafibranor and Seladelpar changing the landscape perfect time to learn more.Elafibranor: https://www.nejm.org/doi/full/10.1056/NEJMoa2312100Seladelpar: https://www.nejm.org/doi/10.1056/NEJMoa2312100?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Join Dr Rohit Gupta has we discuss PBC management and identifying the right patient for second line treatment. Covering: Assessing biochemical response to UDCA, high risk patients, who to consider for second line treatment and aiming for a normal ALP. Primary biliary cholangitis: Personalizing second-line therapies: https://pubmed.ncbi.nlm.nih.gov/39707635/ Hosted by Dr Lucy Vaux

Join Prof Alex Thompson as we discuss stopping hepatitis B medications. We discuss stopping criteria and role of sAg quantification. Topic: Hepatitis B Treatment Guest: Prof Alex Thompson7 minute hepatology team: Rohit Gupta, Lucy Vaux, Laurence Vaitiekunas, Megan Van Niekerk

Join Prof Alex Thompson as we discuss treating patients with Hepatitis C with renal impairment, cirrhosis and genotype 3, failed DAA and role of ribavirin. Hosted by Dr Laurence Vaitekunas. GESA Guidelines on Hepatitis C:hepatitis C virus infection a consensus statement 2022.pdfNEJM Article:Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection | New England Journal of Medicine

Dr Rajit Gilhotra joins our host, Dr Shamya Putta, as he discusses thrombin vs glue, when would you do EUS coiling over BRTO, complications of EUS coiling and investigations post coiling.

Join Dr Sood as we discuss when you should start longterm albumin for your patients with decompensated cirrhosis.

Join A/Prof Marie Sinclair as she discusses home terlipressin covering indications, precautions, patient factors and monitoring